4-氯-5H-吡咯并[3,2-D]嘧啶-7-羧酸 | 1019056-31-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 4-氯-5H-吡咯并[3,2-D]嘧啶-7-羧酸
• 中文别名: 4-氯-5H-吡咯并[3,2-d]嘧啶-7-甲酸；4-氯-5H-吡咯[3,2-D]嘧啶-7-甲酸
• 英文名称: 4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carboxylic acid
• CAS: 1019056-31-5
• 化学式: C₇H₄ClN₃O₂
• mdl: MFCD09999221
• 分子量: 197.581
• InChiKey: SYUREEKHRDWOJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氯-5H-吡咯并[3,2-D]嘧啶-7-羧酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carbonyl chloride
  参考文献：
  名称：

  Inhibitors of HIV-1 attachment. Part 11: The discovery and structure–activity relationships associated with 4,6-diazaindole cores

  摘要：

  A series of HIV-1 attachment inhibitors containing a 4,6-diazaindole core were examined in an effort to identify a compound which improved upon the potency and oral exposure of BMS-488043 (2). BMS-488043 (2) is a 6-azaindole-based HIV-1 attachment inhibitor which established proof-of-concept for this mechanism in human clinical studies but required high doses and concomitant administration of a high fat meal to achieve efficacious exposures. Based on previous studies in indole and azaindole scaffolds, SAR investigation was concentrated around the key 7-position in the 4,6-diazaindole series and led to the discovery of molecules with 5- to 20-fold increases in potency and three-to seven-fold increases in exposure over 2 in a rat PK studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.118
• 作为产物：
  描述：

  4-氯-5氢-吡咯并[3,2-D]嘧啶-7-甲酸乙酯 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 4-氯-5H-吡咯并[3,2-D]嘧啶-7-羧酸
  参考文献：
  名称：

  Inhibitors of HIV-1 attachment. Part 11: The discovery and structure–activity relationships associated with 4,6-diazaindole cores

  摘要：

  A series of HIV-1 attachment inhibitors containing a 4,6-diazaindole core were examined in an effort to identify a compound which improved upon the potency and oral exposure of BMS-488043 (2). BMS-488043 (2) is a 6-azaindole-based HIV-1 attachment inhibitor which established proof-of-concept for this mechanism in human clinical studies but required high doses and concomitant administration of a high fat meal to achieve efficacious exposures. Based on previous studies in indole and azaindole scaffolds, SAR investigation was concentrated around the key 7-position in the 4,6-diazaindole series and led to the discovery of molecules with 5- to 20-fold increases in potency and three-to seven-fold increases in exposure over 2 in a rat PK studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.118

文献信息

• Diazaindole-dicarbonyl-piperazinyl antiviral agents
  申请人：Bender A. John

  公开号：US20050124623A1

  公开（公告）日：2005-06-09

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of — may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  这项发明包括通式I的替代二氮杂吲哚-二羰基-哌嗪基衍生物，其中：Q选自由一组，可以表示成键；T为—C(O)—或—CH(CN)—；以及—Y—选自由一组，包括其组成物及其用于治疗HIV感染的用途。
• DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS
  申请人：Bender John A.

  公开号：US20080125439A1

  公开（公告）日：2008-05-29

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of -- may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  该发明涉及一种一般式I的取代的二氮杂吲哌唑-二羧酰基-哌嗪基衍生物，其中：Q选自由以下组成的群：-可能代表键；T为-C（O）-或-CH（CN）-；和-Y-选自由以下组成的群：其组成物及其用于治疗HIV感染的用途。
• US7902204B2
  申请人：——

  公开号：US7902204B2

  公开（公告）日：2011-03-08
• [EN] BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS<br/>[FR] DÉRIVÉS DE BORONATE HÉTÉROARYLE BICYCLIQUES UTILISÉS COMME INHIBITEURS DE L'ECTO-NUCLÉOTIDE PYROPHOSPHATASE/PHOSPHODIESTÉRASE 1
  申请人：[en]RIBOSCIENCE LLC

  公开号：WO2022197734A1

  公开（公告）日：2022-09-22

  The present disclosure provides certain bicyclic heteroaryl boronate compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.